CHI Statement on Outcome of AB 463
FOR IMMEDIATE RELEASE:
April 29, 2015
|CHI Statement on Outcome of AB 463|
SACRAMENTO – April 29, 2015 – Eve Bukowski, vice president of state government affairs for the California Healthcare Institute (CHI), a non-profit representing more than 275 leading life sciences organizations, issued the following statement regarding the outcome of Assembly Bill (AB) 463 in the California State Assembly Committee on Health:
“Yesterday was a good day for patients, as AB 463 was not brought up for a vote in the California State Assembly Committee on Health.
“We remain opposed to AB 463, as it would have done nothing to ensure patient access to necessary treatments, exclusively targeted a sector providing life saving medicines, and failed to recognize the clinical and economic value to patients and the healthcare system provided by these life saving medications.
“Continued development of new medicines is an essential part of the solution to improving healthcare for all, transforming patient care, averting premature death, and returning a net economic benefit to society.”
Click here to view CHI’s previous statement on AB 463.
About CHI-California Healthcare Institute
CHI represents more than 275 leading biotechnology, medical device, diagnostics and pharmaceutical companies, and public and private academic biomedical research organizations. CHI’s mission is to advance biomedical research, investment and innovation through effective advocacy of policies to improve public health and ensure continued vitality of the life sciences sector. CHI’s website is www.chi.org. Follow us on Twitter @calhealthcare, Facebook, LinkedIn and YouTube.
Manager – Communications, California Healthcare Institute
Phone: (619) 961-8848